Abstracts Archive - Page 753 of 2607 - ACR Meeting Abstracts

Abstract Number: 0718 • ACR Convergence 2021
Pain Severity and Interference in Adult Autoimmune Inflammatory Myopathies
Harmony Tsui¹, Mianbo Wang², Mathieu Piché³, Alexandra Ladouceur⁴, Evelyne Vinet⁵, Alexandra Albert⁶, Maggie Larche⁷, Annaliese Tisseverasinghe⁸, Marie Hudson¹ and Valerie Leclair⁹, ¹McGill University, Montréal, QC, Canada, ²Lady Davis institute for Medical Research, Montréal, QC, Canada, ³Université du Québec à Trois-Rivières, Trois-Rivières, QC, Canada, ⁴McGill University Health Center, Montréal, QC, Canada, ⁵McGill University Health Centre, Mont Royal, QC, Canada, ⁶CHU de Quebec, Québec City, QC, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹McGill University, Karolinska Insitutet, Montréal, QC, Canada
Background/Purpose: Although pain is one of the most common and highest priority symptoms reported by people with autoimmune inflammatory myopathies (AIM), large descriptive studies on…
Abstract Number: 0719 • ACR Convergence 2021
Increased Risk of Venous Thromboembolism in Adult Patients with Idiopathic Inflammatory Myopathies
Gözde Kübra Yardımcı¹, Arzu Taghiyeva², Enes Erul², Bayram Farisogulları³, Levent Kilic¹ and Sule Apraş Bilgen¹, ¹Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²HACETTEPE UNIVERSITY, Ankara, Turkey, ³Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Hacettepe University, Ankara, Turkey
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) patients have a higher risk of venous thromboembolism (VTE) [1]. We aimed to assess the incidence of thrombosis and associated…
Abstract Number: 0720 • ACR Convergence 2021
The Clinical Significance of anti-PC4 and SFRS1 Interacting Protein 1 Antibody in Polymyositis and Dermatomyositis Patients
Yuji Hosono¹, Azusa Kojima¹, Akira Ishii¹, Yuto Izumi¹, Kazuki Hirano¹, Noriko Sasaki², Chiho Yamada¹ and Shinji Sato³, ¹Tokai University School of Medicine, Isehara, Japan, ²tokai university, sagamihara-city, Japan, ³Tokai University, Isehara, Japan
Background/Purpose: Many kinds of myositis specific autoantibodies are detected in sera from polymyositis (PM) and dermatomyositis (DM). Screening for autoantibodies is essential in the diagnostic…
Abstract Number: 0721 • ACR Convergence 2021
Timed Function Tests as Measures of Disease Activity and Functional Outcome in Inflammatory Myositis
saikumar dunga¹, Chengappa Kavadichanda² and VirSingh Negi³, ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²JIPMER, Pondicherry, India, ³Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India
Background/Purpose: Manual muscle testing (MMT) and Functional index 2(FI-2) are the usual methods in assessing disease activity and functional status in IIM1. Limitations of MMT8…
Abstract Number: 0722 • ACR Convergence 2021
Myostatin in Idiopathic Inflammatory Myopathies: Seric Assessment and Disease Activity
Alexandrine Mahoudeau¹, Céline Anquetil², Nozomu Tawara¹, Hossein Khademian¹, Damien Amelin¹, Yves Allenbach³ and Olivier Benveniste³, ¹Center of Research in Myology, Sorbonne University, Paris, France, ²Center of Research in Myology, Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France, ³Sorbonne University - AP-HP, Pitié-Salpêtrière Hospital, Department of Clinical Immunology and Internal Medicine, Paris, France
Background/Purpose: In Idiopathic Inflammatory Myopathies (IIM) disease activity is very difficult to assess and IIM may induce severe muscle damage, especially in immune-mediated necrotizing myopathies…
Abstract Number: 0723 • ACR Convergence 2021
Size of Regression to the Mean in First-Line Interventions for Osteoarthritis: An Illusion of Effectiveness
Martin Englund and Aleksandra Turkiewicz, Lund University, Lund, Sweden
Background/Purpose: Persons who seek treatment for osteoarthritis (OA) are likely doing so when experiencing a flare-up in pain. Due to natural fluctuation of pain, this…
Abstract Number: 0724 • ACR Convergence 2021
Dose (Exposure) Efficacy Response of Tanezumab Following Intravenous and Subcutaneous Administration Across Phase 2 and Phase 3 Studies in Patients with Osteoarthritis of Hip and Knee
Martin Boucher¹, Kenneth Verburg², Puneet Gaitonde² and Scott marshall¹, ¹Pfizer R&D Ltd., Sandwich, United Kingdom, ²Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a humanized monoclonal antibody against nerve growth factor that has been evaluated for relief of chronic osteoarthritis pain by subcutaneous (SC) or…
Abstract Number: 0725 • ACR Convergence 2021
Efficacy of Subcutaneous Tanezumab for the Treatment of Osteoarthritis of the Knee or Hip: A Post Hoc Subgroup Analysis of Patients from a Randomized, NSAID-Controlled Study with a History of Depression, Anxiety, or Insomnia
Philip Mease¹, Theresa Mallick-Searle², Elizabeth Johnston³, Lars Viktrup³, Dominique Menuet⁴, Ruoyong Yang⁵ and Robert Fountaine⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford Health Care, Redwood City, ³Eli Lilly and Company, Indianapolis, IN, ⁴Pfizer SAS, Paris, France, ⁵Pfizer Inc., New York, NY, ⁶Pfizer Inc., Groton, CT
Background/Purpose: Tanezumab is a monoclonal antibody directed against nerve growth factor that is under study to treat moderate to severe chronic pain associated with osteoarthritis…
Abstract Number: 0726 • ACR Convergence 2021
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Robert Fountaine¹, Robert Dworkin², Anne Hickman¹, Glenn Pixton³, Ed Whalen⁴, Christine West¹ and Kenneth Verburg¹, ¹Pfizer Inc., Groton, CT, ²University of Rochester, Rochester, NY, ³Pfizer Inc., Morrisville, NC, ⁴Pfizer Inc., New York, NY
Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
Abstract Number: 0727 • ACR Convergence 2021
Total Joint Replacements in Three Phase 3 Studies of Tanezumab in Patients with Osteoarthritis
John Carrino¹, Timothy McAlindon², Eric Vignon³, Mark Brown⁴, Aimee Burr⁴, Robert Fountaine⁴, Glenn Pixton⁵, Lars Viktrup⁶, Christine West⁴ and Kenneth Verburg⁴, ¹Hospital for Special Surgery, New York, NY, ²Tufts Medical Center, Arlington, MA, ³Université Claude Bernard Lyon 1, Lyon, France, ⁴Pfizer Inc., Groton, CT, ⁵Pfizer Inc., Morrisville, NC, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Tanezumab (TNZ) is an antibody against nerve growth factor that has demonstrated efficacy in the management of osteoarthritis (OA). Due to the potential risk…
Abstract Number: 0728 • ACR Convergence 2021
Intra-articular Canakinumab (anti-interleukin-1β) for Treatment of Symptomatic Knee Osteoarthritis: A Randomized, Double-blind, Placebo and Naproxen-controlled Phase II Study
Philip Conaghan¹, Xavier Chevalier², Linda Mindeholm³, Ursula Schramm³, Jens Praestgaard³, Abdelkader Seroutou³, Ronenn Roubenoff³ and Matthias Schieker³, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Henri Mondor University Hospital and Paris University XII, UPEC, Créteil, France, Créteil, France, ³Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland
Background/Purpose: Knee osteoarthritis (OA) is a common musculoskeletal disease associated with pain and functional impairment. There are few effective therapies, often limited by side-effects.1 This…
Abstract Number: 0729 • ACR Convergence 2021
A Multicenter, Observational, Extension Study Evaluating the Safety, Tolerability, and Efficacy of a Single Lorecivivint Injection in Knee OA Subjects
Ismail Simsek¹, Christopher Swearingen¹, Heli Ghandehari¹, Sarah Kennedy², Jeyanesh Tambiah¹, Yusuf Yazici³ and Nebojsa Skrepnik⁴, ¹Biosplice Therapeutics, Inc., San Diego, CA, ²Biosplice Therapeutics, Inc, San Diego, CA, ³New York University School of Medicine, La Jolla, CA, ⁴Tucson Orthopaedic Institute, Tucson
Background/Purpose: Lorecivivint (LOR), a novel intra-articular (IA) CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways, is in development as a knee osteoarthritis (OA) treatment. To…
Abstract Number: 0730 • ACR Convergence 2021
Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
Amy Halseth¹, Nancy Lane², Sarah Kennedy³, Christopher Swearingen¹, Victor Lopez¹, Ismail Simsek¹, Mark Fineman¹ and Yusuf Yazici⁴, ¹Biosplice Therapeutics, Inc., San Diego, CA, ²University of California Davis, Hillsborough, CA, ³Biosplice Therapeutics, Inc, San Diego, CA, ⁴New York University School of Medicine, La Jolla, CA
Background/Purpose: Knee osteoarthritis (OA) is a painful condition leading to joint damage and impaired function. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat pain.…
Abstract Number: 0731 • ACR Convergence 2021
An Open-Label Study to Evaluate the Effect of Intra-articular Triamcinolone Acetonide Extended Release on Patients with Baseline Synovitis and Osteoarthritis of the Knee
Kim Huffman¹, Alan Kivitz², Philip Conaghan³, Michael Bowes⁴, Alan Brett⁴, Virginia Kraus¹, William Maloney⁵, Javad Parvizi⁶, Amy Cinar⁷, Neil Bodick⁷ and Scott Kelley⁷, ¹Duke University School of Medicine, Durham, NC, ²Altoona Center for Clinical Research, Duncansville, PA, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Imorphics Ltd, Manchester, United Kingdom, ⁵Stanford University School of Medicine, Stanford, CA, ⁶Thomas Jefferson University Hospital, Philadelphia, PA, ⁷Flexion Therapeutics Inc., Burlington, MA
Background/Purpose: Synovial inflammation is common in knee osteoarthritis (OA) and is associated with pain and disease severity. Previous studies have suggested short-term (approximately 2 weeks)…
Abstract Number: 0732 • ACR Convergence 2021
Topical Rofecoxib for OA of the Knee
Bruce Register¹, Nancy Lane², Lee Simon³, John Newsam⁴, Edward Kisak⁴, Jed Pheneger⁵, John Galvin⁵, Jeffrey Klein⁶ and Marc Hochberg⁷, ¹BriOri BioTech, Inc., Newport Beach, CA, ²University of California Davis, Hillsborough, CA, ³SDG LLC, West Newton, MA, ⁴Tioga Research, Inc, San Diego, CA, ⁵Inotiv, Boulder, CO, ⁶Sinclair Research Center, Auxvasse, MO, Canada, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].